Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

Metwally MA, Frederiksen KD, Overgaard J.

Acta Oncol. 2014 May;53(5):654-61. doi: 10.3109/0284186X.2013.864050.

PMID:
24328536
2.

Treatment of head and neck cancer with CHART and nimorazole: phase II study.

Henk JM, Bishop K, Shepherd SF.

Radiother Oncol. 2003 Jan;66(1):65-70.

PMID:
12559522
3.

Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.

Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J.

Acta Oncol. 2015 Jul;54(7):1001-7. doi: 10.3109/0284186X.2014.992547.

PMID:
25629651
4.

Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.

Cottrill CP, Bishop K, Walton MI, Henk JM.

Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):807-10.

PMID:
9845101
5.

IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.

Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, Prasad R, Grau C, Overgaard J.

Radiother Oncol. 2015 Jul;116(1):15-20. doi: 10.1016/j.radonc.2015.04.005.

PMID:
25913070
6.

Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.

Hassan Metwally MA, Jansen JA, Overgaard J.

Clin Oncol (R Coll Radiol). 2015 Mar;27(3):168-75. doi: 10.1016/j.clon.2014.11.024.

PMID:
25530485
7.
8.

Evidence-based radiation oncology in head and neck squamous cell carcinoma.

Corvò R.

Radiother Oncol. 2007 Oct;85(1):156-70. Review.

PMID:
17482300
9.

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF.

Lancet. 2003 Sep 20;362(9388):933-40. Erratum in: Lancet. 2003 Nov 8;362(9395):1588.

PMID:
14511925
10.

Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.

Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87.

PMID:
15380569
11.

Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.

Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J; Danish Head and Neck Cancer Group (DAHANCA)..

Radiother Oncol. 2012 Jan;102(1):122-9. doi: 10.1016/j.radonc.2011.09.010.

PMID:
21996521
12.

NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.

Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, Slevin N.

Clin Oncol (R Coll Radiol). 2014 Jun;26(6):344-7. doi: 10.1016/j.clon.2014.03.003. No abstract available.

PMID:
24685344
13.

Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.

Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM.

Br J Cancer. 2008 Jul 8;99(1):57-62. doi: 10.1038/sj.bjc.6604444.

14.

Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.

Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Overgaard J, Grau C.

Acta Oncol. 2015;54(9):1673-7. doi: 10.3109/0284186X.2015.1074721. No abstract available.

PMID:
26397148
15.
16.

Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.

Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, Bamberg M.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):691-6.

PMID:
9240634
17.
18.

Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.

Overgaard J, Sand Hansen H, Lindeløv B, Overgaard M, Jørgensen K, Rasmusson B, Berthelsen A.

Radiother Oncol. 1991;20 Suppl 1:143-9.

PMID:
2020763
19.

Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

Ali EM, Abdelraheem AG.

Head Neck Oncol. 2011 Nov 15;3:48. doi: 10.1186/1758-3284-3-48.

20.

Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.

Vivek RS, Baludavid M, Mohanram R; Chitra.; Amanullah.; Vijayalakshmi.; Bala.; Kalaiyarasi.; Saravanan..

J Cancer Res Ther. 2006 Jul-Sep;2(3):90-6.

Supplemental Content

Support Center